Eli Lilly Israel Ltd

Antimetabolite (antifolate). Pemetrexed 100 mg, 500 mg.
VIAL: 1X 100 mg, 500 mg. Comb. use
with cisplatin: 500 mg/m2 I.V. over 10
mins. on day 1 of each 21-day cycle.
Recommend. dose cisplatin: 75 mg/m2
I.V. over 2 hrs. begin. 30 mins. aft. end
of Alimta admin.
Monother: 500 mg/m2 IV over 10 mins.
on the 1 day of each 21-day cycle. See
lit.
In comb. with cisplatin for tmt.: malignant
pleural mesothelioma whose dis.
unresectable or otherwise not candidates
for curative surg.; first line tmt. locally
advanced/ metastat. non-small cell
lungcancer other than predom. Squamous
cell histology. As monother: in local.
advanced/ metastat. non-small cell lung
cancer other than predom. squamous cell
histology histology in patients whose dis.
has not progressed immediately following
platinum-based chemotherapy; second
line tmt. locally advanced/metastat.
nonsmall cell lung cancer, other than
predom. squamous cell histology.
C/I: Hypersens., lact., concom. yellow
fever vaccine.

Long Acting Insulin. Insulin Glargine 100 U/ml.
Cartridge (sol. for inj.): 5×3 ml
Pre-filled Pen (sol.for inj.): 5 ×3 ml
Should be admin. once dly. at any time but at the same time each day.
Dose regimen should be individ. adjust. In pts. with type 2 diabetes mell., the drug can also be given together with orally active antidiabetic med. products.
The potency of this med. product is stated in units. These units are exclusive to insulin glargine and are not the same as IU or the units used to express the potency of other insulin analog. See lit.
Tmt. of adult pts. 18 yrs. and over with type 1 or type 2 diabetes mell. who require basal (long act.) insulin for the control of hyperglycaem.
C/I: Hypersens.

Phosphodiesterase-5 Enzyme Inhibitor. Tadalafil 2.5, 5, 10, 20 mg.
F.C. TABS: 4 x 10 mg; 4, 8 x 20 mg.
On-demand: 10 mg or 20 mg,
depend. response, 30 mins. - 12 hrs
bef. sexual activity. Effic. may persist
for up to 36 hrs. Max: 1 dose dly, but
dly use not recommend. Childr. under
18 yrs: not recommend.
Tmt. erect. dysfunct. in men.
F.C. TABS: 28 x 2.5 mg, 5 mg. Once /d:
For men who anticipate freq. use (min.
2 x wkly): 2.5 mg/5 mg 1 x dly, depend.
on individ. tolerabil. Reassess period.
Tmt. erect. dysfunct. in men.
5 mg only: Tmt. erect. dysfunct. in men. Tmt of the signs, symptoms of BPH. Tmt of ED and the signs and symptoms of BPH (ED/BPH).
C/I:Hypersens./ concom. use of  of organic nitrate/
Pts. with cardiac dis. for whom sexual activity is inadvisable/
pts. with MI within the last 90 days/
pts.with unstable angina or angina occurring during sexual intercourse/
pts. with NYHA Class 2 or greater HF in the last 6 months/
pts.with uncontrolled arrhythmias, hypotension (<90/50 mm Hg), or uncontrolled hypertension/pts. with a stroke within the last 6 months/
pts. who have loss of vision in one eye because of non-arteritic anterior
ischemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhib. exposure/ co-admin. of PDE5 inhib., incl. tadalafil, with guanylate cyclase stimulators, such as riociguat.

SNRI. Duloxetine HCl 30 mg, 60 mg.
CAPS: 7,14,28 x 30 mg, 60 mg.
intial: 30 mg dly. maint: 60 mg dly.
Ther. response: 2-4 wks aft. tmt. To
discont: Taper by 1/2 dose (30 mg) dly
or on alt. days. See lit.
Major depress. episodes., Generalized
anxiety dis., Neuropath. pain assoc.
with diabet. periph. neuropathy.,
fibromyalg., chron. muscoskeletal pain.
C/I: Concom. use with MAOI,
uncontrolled narrow-angle glaucoma.

Calcitonin gene-related peptide (CGRP) antagonists.. Galcanezumab 120 mg.
Sol. for inject. in pre-filled pen 1 or 2 X 120 mg in 1 ml.
Recommended dose is 120 mg injected SC once monthly, with a
240 mg loading dose as the initial dose.
Prophylaxis of migraine in adults who have at least 4 migraine days/mo.
C/I: Hypersens.

Selective Estrogen Receptor Modulator (SERM). Raloxifene HCl 60 mg.
F.C. TABS: 28. 1 tab. dly without regard to
meals.
Tmt. osteoporos. in post-menopaus.
women. Tmt., prevent. osteoporos. in postmenopaus.
women in whom estrogen
ther. unsuitable. Reduct. risk invasive
breast cancer in postmenopaus. women
with osteoporos. Reduct. risk invasive
breast cancer in women at high risk of
invasive breast cancer.
C/I: Pregn. or possibility thereof, lact.,
active/history of venous thromboembol.
events, deep vein thrombos.,
pulm. embol., retinal vein thromb.